Modeling Nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials

Lisa Shubitz, Hien T. Trinh, Robert H. Perrill, C. Michael Thompson, Nathan J. Hanan, John N Galgiani, David E. Nix

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Nikkomycin Z (NikZ) is a chitin synthase inhibitor with activity against Coccidioides species that is being developed as a first-in-class orphan product for treatment of coccidioidomycosis. It has previously been shown to reduce lethal respiratory infections in mice to undetectable levels when treatment is begun 48 hours after infection. The studies described here focus on bracketing NikZ doses for phase 2 and 3 clinical trials, using an established mouse respiratory infection as a model and starting treatment 120 hours after infection. A dose of 80 mg/kg/day, divided into 2 doses, nearly eradicated infection, and larger doses did not improve fungal clearance. Increasing the duration of treatment from 1 week to 3 weeks resulted in a greater percentage of culture-negative mice. Comparative data show that plasma levels of NikZ that nearly eradicate Coccidioides in mice are achievable in patients and provide a plausibly effective dose range for initial phase 2 clinical studies.

Original languageEnglish (US)
Pages (from-to)1949-1954
Number of pages6
JournalJournal of Infectious Diseases
Volume209
Issue number12
DOIs
StatePublished - Jun 15 2014

Fingerprint

Coccidioidomycosis
Clinical Trials
Coccidioides
Pharmacology
Lung
Respiratory Tract Infections
Infection
Chitin Synthase
Phase III Clinical Trials
Orphaned Children
Therapeutics
nikkomycin

Keywords

  • anti-fungal drugs
  • coccidioidomycosis
  • experimental infection
  • Mouse
  • nikkomycin Z
  • pharmacokinetics

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Modeling Nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials. / Shubitz, Lisa; Trinh, Hien T.; Perrill, Robert H.; Thompson, C. Michael; Hanan, Nathan J.; Galgiani, John N; Nix, David E.

In: Journal of Infectious Diseases, Vol. 209, No. 12, 15.06.2014, p. 1949-1954.

Research output: Contribution to journalArticle

@article{14d8d90e394f4b72bf8bb17e60cc40aa,
title = "Modeling Nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials",
abstract = "Nikkomycin Z (NikZ) is a chitin synthase inhibitor with activity against Coccidioides species that is being developed as a first-in-class orphan product for treatment of coccidioidomycosis. It has previously been shown to reduce lethal respiratory infections in mice to undetectable levels when treatment is begun 48 hours after infection. The studies described here focus on bracketing NikZ doses for phase 2 and 3 clinical trials, using an established mouse respiratory infection as a model and starting treatment 120 hours after infection. A dose of 80 mg/kg/day, divided into 2 doses, nearly eradicated infection, and larger doses did not improve fungal clearance. Increasing the duration of treatment from 1 week to 3 weeks resulted in a greater percentage of culture-negative mice. Comparative data show that plasma levels of NikZ that nearly eradicate Coccidioides in mice are achievable in patients and provide a plausibly effective dose range for initial phase 2 clinical studies.",
keywords = "anti-fungal drugs, coccidioidomycosis, experimental infection, Mouse, nikkomycin Z, pharmacokinetics",
author = "Lisa Shubitz and Trinh, {Hien T.} and Perrill, {Robert H.} and Thompson, {C. Michael} and Hanan, {Nathan J.} and Galgiani, {John N} and Nix, {David E.}",
year = "2014",
month = "6",
day = "15",
doi = "10.1093/infdis/jiu029",
language = "English (US)",
volume = "209",
pages = "1949--1954",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Modeling Nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials

AU - Shubitz, Lisa

AU - Trinh, Hien T.

AU - Perrill, Robert H.

AU - Thompson, C. Michael

AU - Hanan, Nathan J.

AU - Galgiani, John N

AU - Nix, David E.

PY - 2014/6/15

Y1 - 2014/6/15

N2 - Nikkomycin Z (NikZ) is a chitin synthase inhibitor with activity against Coccidioides species that is being developed as a first-in-class orphan product for treatment of coccidioidomycosis. It has previously been shown to reduce lethal respiratory infections in mice to undetectable levels when treatment is begun 48 hours after infection. The studies described here focus on bracketing NikZ doses for phase 2 and 3 clinical trials, using an established mouse respiratory infection as a model and starting treatment 120 hours after infection. A dose of 80 mg/kg/day, divided into 2 doses, nearly eradicated infection, and larger doses did not improve fungal clearance. Increasing the duration of treatment from 1 week to 3 weeks resulted in a greater percentage of culture-negative mice. Comparative data show that plasma levels of NikZ that nearly eradicate Coccidioides in mice are achievable in patients and provide a plausibly effective dose range for initial phase 2 clinical studies.

AB - Nikkomycin Z (NikZ) is a chitin synthase inhibitor with activity against Coccidioides species that is being developed as a first-in-class orphan product for treatment of coccidioidomycosis. It has previously been shown to reduce lethal respiratory infections in mice to undetectable levels when treatment is begun 48 hours after infection. The studies described here focus on bracketing NikZ doses for phase 2 and 3 clinical trials, using an established mouse respiratory infection as a model and starting treatment 120 hours after infection. A dose of 80 mg/kg/day, divided into 2 doses, nearly eradicated infection, and larger doses did not improve fungal clearance. Increasing the duration of treatment from 1 week to 3 weeks resulted in a greater percentage of culture-negative mice. Comparative data show that plasma levels of NikZ that nearly eradicate Coccidioides in mice are achievable in patients and provide a plausibly effective dose range for initial phase 2 clinical studies.

KW - anti-fungal drugs

KW - coccidioidomycosis

KW - experimental infection

KW - Mouse

KW - nikkomycin Z

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84901759593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901759593&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu029

DO - 10.1093/infdis/jiu029

M3 - Article

C2 - 24421256

AN - SCOPUS:84901759593

VL - 209

SP - 1949

EP - 1954

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -